Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

Rhea-AI Summary

Eton Pharmaceuticals, Inc. will report its third quarter 2023 financial results on November 9, 2023. The company focuses on developing, acquiring, and commercializing products for rare diseases. A conference call and live webcast will be held to discuss the results. Participants can also email questions to investorrelations@etonpharma.com. The webcast will be available on Eton's website.

DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced that it will report third quarter 2023 financial results on Thursday, November 9, 2023. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).

Register* (Audio Only)         Click here

In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.

The live webcast can be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.

* Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases. The Company currently has four FDA-approved rare disease products, ALKINDI SPRINKLE® for the treatment of pediatric adrenocortical insufficiency, Carglumic Acid for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency, Betaine Anhydrous for the treatment of homocystinuria, and Nitisinone for the treatment of hereditary tyrosinemia type 1. The Company has four additional product candidates in late-stage development: ET-400 for the treatment of adrenocortical insufficiency, ET-600 for the treatment of diabetes insipidus, ZENEO® hydrocortisone autoinjector for the treatment of adrenal crisis, and dehydrated alcohol injection for the treatment of methanol poisoning. For more information, please visit our website at www.etonpharma.com.

Investor Relations:

Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Source: Eton Pharmaceuticals

FAQ

When will Eton Pharmaceuticals report its third quarter 2023 financial results?

Eton Pharmaceuticals will report its third quarter 2023 financial results on November 9, 2023.

What does Eton Pharmaceuticals focus on?

Eton Pharmaceuticals focuses on developing, acquiring, and commercializing products for rare diseases.

How can investors participate in the conference call?

Investors can participate in the conference call by registering to obtain their dial-in and passcode details.

How long will the webcast be available?

The webcast will be available on Eton's website for approximately two hours after the event and for 30 days thereafter.